Segregating two inhibitory circuits in human motor cortex at the level of GABAA receptor subtypes: a TMS study.
OBJECTIVE
To investigate if different interneuronal circuits in human motor cortex mediate inhibition through different subtypes of the gamma-aminobutyric acid A receptor (GABAAR).


METHODS
Two distinct forms of motor cortical inhibition were measured in 10 healthy subjects by established transcranial magnetic stimulation (TMS) protocols: short interval intracortical inhibition (SICI) and short latency afferent inhibition (SAI). Their modification by a single oral dose of three different positive GABAAR modulators (20 mg of diazepam, 2.5 mg of lorazepam and 10 mg of zolpidem) with different affinity profiles at the various alpha-subunit bearing subtypes of the GABAAR (diazepam: non-selective, lorazepam: unknown, zolpidem: 10-fold higher affinity to alpha1- than alpha2- or alpha3-subunit bearing GABAARs, no affinity to alpha5-subunits) was tested in a randomized crossover design. In addition, the sedative drug effects were recorded by a visual analogue scale.


RESULTS
Diazepam and lorazepam increased SICI, whereas zolpidem did not change SICI. In contrast, diazepam had no effect on SAI, whereas lorazepam and zolpidem decreased SAI. The sedative effects were not different between drugs.


CONCLUSIONS
The dissociating patterns of drug modification of SICI versus SAI strongly suggest that different GABAAR subtypes are involved in SICI and SAI.


CONCLUSIONS
We provide evidence, for the first time, for a dissociation of effects of diazepam and zolpidem on SAI and confirm the previously reported differential effect of zolpidem and of diazepam and lorazepam on SICI. The differential effects of the three benzodiazepines on SAI and SICI suggest that neuronal circuits in human motor cortex that mediate inhibition through different GABAAR subtypes can be segregated by TMS.
Di Lazzaro
V
V
Institute of Neurology, Università Cattolica, L go A Gemelli 8, 00168 Rome, Italy. vdilazzaro@rm.unicatt.it
Pilato
F
F
Dileone
M
M
Profice
P
P
Ranieri
F
F
Ricci
V
V
Bria
P
P
Tonali
P A
PA
Ziemann
U
U
D000328:Adult; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology; D018592:Cross-Over Studies; D003975:Diazepam / Q000494:pharmacology; D019054:Evoked Potentials, Motor / Q000187:drug effects; D018755:GABA Agonists / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008140:Lorazepam / Q000494:pharmacology; D009044:Motor Cortex / Q000502:physiology*; D009475:Neurons, Afferent / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology*; D050781:Transcranial Magnetic Stimulation; D000077334:Zolpidem
D018755:GABA Agonists; D018757:GABA Modulators; C546240:GABRA1 protein, human; D006993:Hypnotics and Sedatives; D011725:Pyridines; D011963:Receptors, GABA-A; D000077334:Zolpidem; D008140:Lorazepam; D003975:Diazepam